Beximco Pharmaceuticals Ltd.
BXP | IL
Overview
Corporate Details
- ISIN(s):
- US0885792061
- LEI:
- 213800IMBBD6TIOQGB56
- Country:
- Bangladesh
- Address:
- N/A
- Website:
- https://www.beximcopharma.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-13 17:10 |
Report Publication Announcement
Request of Extension to Publish Q1 Results
|
English | 11.2 KB | ||
| 2025-11-04 08:25 |
Regulatory Filings
Change of Name to Beximco Pharmaceuticals PLC.
|
English | 10.8 KB | ||
| 2025-10-27 16:53 |
Report Publication Announcement
Request of Extension to Publish Financial Results
|
English | 11.3 KB |
Automate Your Workflow. Get a real-time feed of all Beximco Pharmaceuticals Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Beximco Pharmaceuticals Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Beximco Pharmaceuticals Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.
United States of America
OKUR
United States of America
OKUR
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan
4528
Japan
4528
Developing precision-guided therapeutics using small antibodies for complex diseases.
France
ALONX
France
ALONX
A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.
United States of America
OPK
United States of America
OPK
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America
OPT
United States of America
OPT
Develops microbiome-modulating ingredients and supplements to manage chronic lifestyle diseases.
United Kingdom
OPTI
United Kingdom
OPTI
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea
131030
South Korea
131030
Developing gene therapies for inherited retinal diseases and other blinding conditions.
United States of America
IRD
United States of America
IRD
Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.
Israel
ORMP
Israel
ORMP
Develops and distributes point-of-care diagnostic tests and sample collection devices.
United States of America
OSUR
United States of America
OSUR